Full Breakdown
Food and Drug Administration (FDA) Workshop Highlights Gaps in Women’s Testosterone Therapy
By Drooid · · How we work
Current Clinical Landscape
Women entering menopause are increasingly asking for testosterone to address low sexual desire, fatigue and reduced quality of life. Because no testosterone product is FDA-approved for women in the United States, physicians rely on off-label prescribing and custom compounding. The only guideline-backed indication is hypoactive sexual desire disorder (HSDD); evidence for benefits to energy, mood, bone health or sleep remains limited. Clinicians typically use either compounded creams or micro-dose male gel packets, requiring patients to measure doses at home. Insurance companies frequently deny coverage for these off-label uses, forcing patients to pay out-of-pocket or seek cheaper compounded alternatives.
Official Statements & Physician Experiences
Dr. Kudzai Dombo, a board-certified obstetrician-gynecologist at Alloy Health in Los Angeles, described the daily challenges she sees. After patients are stabilized on estrogen and progesterone, “the immediate next question is, do I need testosterone?” She noted that insurance denials often lead her to recommend compounded creams, yet some patients prefer the male gel despite dosing uncertainties.
Verbatim Quotes
- “The immediate next question is, do I need testosterone?” — Dr. Kudzai Dombo
- “When I was prescribed testosterone, my insurance denied coverage, and my physician recommended a compounded cream to avoid the administrative burden,” — Dr. Kudzai Dombo
Implications and Next Steps
The FDA’s public workshop, convened to examine evidence, safety and research gaps, represents a critical step toward potential regulatory action. Physicians and patient advocates argue that continued grassroots pressure is essential to secure safer, standardized access to testosterone for menopausal women. Until formal approvals or clear dosing guidelines emerge, clinicians will likely continue navigating off-label prescriptions, compounded formulations, and patient-driven dosing experiments.